101 related articles for article (PubMed ID: 25919319)
1. Effectiveness, toxicity, and economic evaluation of vinflunine for the treatment of patients with transitional cell carcinoma in the Spanish outpatient setting.
Guglieri-López B; Pérez-Pitarch A; Porta-Oltra B; Ferriols-Lisart F; Climente-Martí M; Alós-Almiñana M
Anticancer Drugs; 2015 Sep; 26(8):860-5. PubMed ID: 25919319
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting.
Guglieri-López B; Pérez-Pitarch A; Porta Oltra B; Ferriols-Lisart F; Royo-Peiró Á; Climente-Martí M
Anticancer Drugs; 2016 Aug; 27(7):679-84. PubMed ID: 27058705
[TBL] [Abstract][Full Text] [Related]
3. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
Castellano D; Puente J; de Velasco G; Chirivella I; López-Criado P; Mohedano N; Fernández O; García-Carbonero I; González MB; Grande E
BMC Cancer; 2014 Oct; 14():779. PubMed ID: 25342282
[TBL] [Abstract][Full Text] [Related]
5. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
Bellmunt J; Kerst JM; Vázquez F; Morales-Barrera R; Grande E; Medina A; González Graguera MB; Rubio G; Anido U; Fernández Calvo O; González-Billalabeitia E; Van den Eertwegh AJM; Pujol E; Perez-Gracia JL; González Larriba JL; Collado R; Los M; Maciá S; De Wit R;
Ann Oncol; 2017 Jul; 28(7):1517-1522. PubMed ID: 28419193
[TBL] [Abstract][Full Text] [Related]
7. Vinflunine.
Prescrire Int; 2011 Jan; 20(112):11-3. PubMed ID: 21462785
[TBL] [Abstract][Full Text] [Related]
8. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
Vaughn DJ; Srinivas S; Stadler WM; Pili R; Petrylak D; Sternberg CN; Smith DC; Ringuette S; de Wit E; Pautret V; George C
Cancer; 2009 Sep; 115(18):4110-7. PubMed ID: 19536904
[TBL] [Abstract][Full Text] [Related]
9. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series.
Palumbo R; Licata L; Sottotetti F; Tagliaferri B; Pozzi E; Teragni C; Quaquarini E; Bernardo A
Oncol Res Treat; 2018; 41(1-2):8-13. PubMed ID: 29402855
[TBL] [Abstract][Full Text] [Related]
10. Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study.
Abdel-Malek R; Shohdy KS; Abbas N; Ismail M; Hamada E; Abdel-Kader Y
Curr Drug Saf; 2019; 14(1):31-36. PubMed ID: 30277164
[TBL] [Abstract][Full Text] [Related]
11. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.
Hussain SA; Ansari J; Huddart R; Power DG; Lyons J; Wylie J; Vilarino-Varlela M; Elander NO; McMenemin R; Pickering LM; Faust G; Chauhan S; Jackson RJ
Int J Oncol; 2017 Mar; 50(3):768-772. PubMed ID: 28098864
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.
Culine S; Theodore C; De Santis M; Bui B; Demkow T; Lorenz J; Rolland F; Delgado FM; Longerey B; James N
Br J Cancer; 2006 May; 94(10):1395-401. PubMed ID: 16622447
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group.
Pistamaltzian N; Tzannis K; Pissanidou V; Peroukidis S; Milaki G; Karavasilis V; Mitsogiannis I; Varkarakis I; Papatsoris A; Dellis A; Adamakis I; Stravodimos K; Molyva D; Athanasiadis I; Androulakis N; Andreadis C; Kalofonos C; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamias A
Anticancer Drugs; 2016 Jan; 27(1):48-53. PubMed ID: 26421462
[TBL] [Abstract][Full Text] [Related]
14. Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials.
Moriceau G; Vallard A; Rivoirard R; Méry B; Espenel S; Langrand-Escure J; Ben Mrad M; Wang G; Diao P; Pacaut C; Guillot A; Collard O; Fournel P; Magné N
Clin Genitourin Cancer; 2015 Dec; 13(6):588-92. PubMed ID: 26117277
[TBL] [Abstract][Full Text] [Related]
15. Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen.
De Luca R; Profita G; Vella M; Cicero G
Oncology; 2019; 97(6):341-347. PubMed ID: 31461721
[TBL] [Abstract][Full Text] [Related]
16. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.
Gerullis H; Ecke TH; Janusch B; Arndt C; Heidari M; Oniani J; Otto T
Anticancer Drugs; 2011 Oct; 22(9):940-3. PubMed ID: 21642839
[TBL] [Abstract][Full Text] [Related]
17. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
Krajewski KM; Fougeray R; Bellmunt J; Pons F; Schutz FA; Rosenberg JE; Salhi Y; Choueiri TK
Eur J Cancer; 2012 Jul; 48(10):1495-502. PubMed ID: 22176867
[TBL] [Abstract][Full Text] [Related]
18. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
[TBL] [Abstract][Full Text] [Related]
19. Second-line therapy in bladder cancer.
Bachner M; De Santis M
Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study.
Pappot H; von der Maase H; Ullén A; Agerbæk M;
Invest New Drugs; 2018 Aug; 36(4):615-618. PubMed ID: 29081023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
